Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses ...

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in...
Streetwise Reports | January 14, 2020 |

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...
Streetwise Reports | December 19, 2019 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. Clinical-stage biopharmaceutical company Fate Thera...
Streetwise Reports | April 7, 2020 |

MEI Pharma Shares Rise 50% on $682.5M Partnership with Japanese Company to Treat B-cell Malignancies

Shares of MEI Pharma traded higher after the company announced that it has entered into development and global licensing agreement with Kyowa Kirin for its oral selective PI3Kd inhibitor (ME-401) used for treating B-cell malignancies. Late-stage pharmaceutic...
Streetwise Reports | April 15, 2020 |

Price-Leading Fuel Cell Technology with Zero CO2 Emissions

A fuel cell is a clean electrical power conversion/generation system, akin to a small power station that provides electricity and an equivalent amount of heat for various purposes. Alkaline Fuel Cell Power Corp. ( NEO.PWWR , Forum ) is at the forefront of this technolo...
Dave Jackson | September 24, 2021 |

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were ...
Streetwise Reports | January 17, 2020 |

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. In an April 9 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Mesoblast Lt...
Streetwise Reports | April 16, 2020 |

Buzz on the Bullboards: Creating Cash out of an Economy Crunch

(Image via Bombardier Inc.) If you’re looking to see the stocks that investors have been keeping an eye on over the past week, you’ve come to the right place. The Stockhouse community regularly acts as a microcosm of investor sen...
Stockhouse Editorial | May 25, 2022 |

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report.
Streetwise Reports | May 14, 2020 |
1 2 3 4 5 6 7 8 9 10 ...